Parthenon LLC boosted its stake in Stryker Corporation (NYSE:SYK) by 2.5% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 44,120 shares of the medical technology company’s stock after acquiring an additional 1,060 shares during the quarter. Stryker Corporation comprises about 1.5% of Parthenon LLC’s holdings, making the stock its 24th largest holding. Parthenon LLC’s holdings in Stryker Corporation were worth $6,266,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. BP PLC boosted its holdings in Stryker Corporation by 12.9% in the 3rd quarter. BP PLC now owns 39,500 shares of the medical technology company’s stock worth $5,610,000 after acquiring an additional 4,500 shares during the period. Ramsay Stattman Vela & Price Inc. boosted its holdings in Stryker Corporation by 0.7% in the 3rd quarter. Ramsay Stattman Vela & Price Inc. now owns 47,418 shares of the medical technology company’s stock worth $6,734,000 after acquiring an additional 315 shares during the period. Brightworth boosted its holdings in Stryker Corporation by 2,755.7% in the 3rd quarter. Brightworth now owns 41,751 shares of the medical technology company’s stock worth $5,930,000 after acquiring an additional 40,289 shares during the period. Westpac Banking Corp boosted its holdings in Stryker Corporation by 18.5% in the 3rd quarter. Westpac Banking Corp now owns 213,525 shares of the medical technology company’s stock worth $30,325,000 after acquiring an additional 33,375 shares during the period. Finally, Boys Arnold & Co. Inc. boosted its holdings in Stryker Corporation by 2.6% in the 3rd quarter. Boys Arnold & Co. Inc. now owns 18,853 shares of the medical technology company’s stock worth $2,677,000 after acquiring an additional 480 shares during the period. Hedge funds and other institutional investors own 74.13% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/parthenon-llc-has-6-27-million-holdings-in-stryker-corporation-syk/1682442.html.

Stryker Corporation (SYK) opened at $156.18 on Monday. The company has a quick ratio of 1.61, a current ratio of 2.37 and a debt-to-equity ratio of 0.63. Stryker Corporation has a one year low of $106.48 and a one year high of $160.62. The firm has a market capitalization of $58,448.43, a P/E ratio of 24.75, a P/E/G ratio of 2.46 and a beta of 0.79.

Stryker Corporation (NYSE:SYK) last issued its quarterly earnings data on Thursday, October 26th. The medical technology company reported $1.52 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.50 by $0.02. Stryker Corporation had a return on equity of 24.11% and a net margin of 14.67%. The business had revenue of $3.01 billion for the quarter, compared to the consensus estimate of $2.97 billion. During the same period last year, the business earned $1.39 EPS. The firm’s revenue was up 6.1% compared to the same quarter last year. research analysts predict that Stryker Corporation will post 6.47 earnings per share for the current fiscal year.

In related news, insider Graham A. Mclean sold 1,124 shares of the firm’s stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $146.26, for a total value of $164,396.24. Following the transaction, the insider now directly owns 8,983 shares of the company’s stock, valued at approximately $1,313,853.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 7.40% of the stock is currently owned by company insiders.

A number of equities analysts have weighed in on SYK shares. Wells Fargo & Company upped their price target on Stryker Corporation from $160.00 to $166.00 in a report on Friday, October 27th. Cowen and Company restated a “buy” rating and issued a $160.00 price target (up previously from $150.00) on shares of Stryker Corporation in a report on Sunday, July 30th. Stifel Nicolaus increased their target price on Stryker Corporation from $151.00 to $158.00 and gave the company a “buy” rating in a research note on Friday, July 28th. Zacks Investment Research upgraded Stryker Corporation from a “hold” rating to a “buy” rating and set a $163.00 target price for the company in a research note on Monday, July 17th. Finally, BidaskClub upgraded Stryker Corporation from a “hold” rating to a “buy” rating in a research note on Thursday, August 17th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and twelve have issued a buy rating to the company. Stryker Corporation currently has a consensus rating of “Hold” and a consensus price target of $151.52.

About Stryker Corporation

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK).

Institutional Ownership by Quarter for Stryker Corporation (NYSE:SYK)

Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.